About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ARWR - Arrowhead Pharmaceut...| Previous Close | $59.10 | Open | $59.69 |
| Volume | 635.5K | Market Cap | 6.023B |
| Yield | Last Dividend |
| Insider Selling: Arrowhead Pharmaceutica... | 10/24/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 29,166 shares of Arrowhead Pharmaceuticals stock in a transaction dated ... | |
| Analysts Anticipate Arrowhead Pharmaceut... | 10/24/20 |
| Equities research analysts expect that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will post sales of $38.62 million for the current quarter, Zacks re... | |
| Arrowhead Pharmaceuticals Inc (NASDAQ:AR... | 10/24/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 100,000 shares of the firm???s stock in a transaction on Friday, Oct... | |
| Christopher Richard Anzalone Sells 100,0... | 10/23/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 100,000 shares of the firm???s stock in a transaction on Friday, Oct... | |
| Arrowhead Pharmaceuticals Inc (NASDAQ:AR... | 10/23/20 |
| Brokerages expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to post $0.33 earnings per share (EPS) for the current fiscal quarter, according to Zack... | |
| Kenneth Allen Myszkowski Sells 29,166 Sh... | 10/22/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 29,166 shares of the stock in a transaction on Tuesday, October 20th. Th... | |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) ... | 10/22/20 |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by equities research analysts at BidaskClub from a ???strong sell??? rating to a ???sell??? ratin... | |
| Arrowhead Pharmaceuticals Target of Unus... | 10/21/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) was the target of unusually large options trading on Tuesday. Stock traders bought 3,214 call options on t... | |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) ... | 10/21/20 |
| BidaskClub upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a strong sell rating to a sell rating in a report issued on Tuesday morning... | |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) ... | 10/20/20 |
| Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)???s stock price was up 9.3% during trading on Tuesday . The stock traded as high as $54.94 and last traded... | |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) ... | 10/19/20 |
| Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by stock analysts at BidaskClub from a ???strong sell??? rating to a ???sell??? rating in a resea... | |
| Why Arrowhead Pharmaceuticals Is Trading... | 10/15/20 |
| Arrowhead Pharmaceuticals (NASDAQ: ARWR ) shares are trading higher on Thursday on news that Vertex Pharmaceuticals discontinued its trial of a drug c... | |
| Hepatitis B Infection Market 2020-2026 i... | 10/15/20 |
| A most recent review on Global Hepatitis B Infection Market is led covering different associations of the business from various topographies to think ... | |
| Targeted Delivery Drugs Market Size, Sha... | 10/14/20 |
| A wide ranging Targeted Delivery Drugs Market report is one of the most significant, unique, and creditable market research reports formed by focusing... | |
| Arrowhead Pharmaceuticals to Participate... | 09/30/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference | |
| Global RNA Interference Market To See As... | 09/30/20 |
| This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece... | |
| Arrowhead Pharmaceuticals News: Why ARWR... | 09/16/20 |
| Arrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher. | |
| Why Arrowhead Pharma's Stock Is Trading ... | 09/16/20 |
| Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy resu... | |
| Arrowhead Pharmaceuticals to Participate... | 09/08/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020 | |
| Arrowhead Presents Positive New Phase 1/... | 08/31/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidat... | |
| Arrowhead Pharmaceuticals Initiates Phas... | 08/18/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell ... | |
| Arrowhead Pharmaceuticals Initiates Dosi... | 08/11/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis | |
| Arrowhead Pharmaceuticals Reports Fiscal... | 08/05/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal Q3 2020 earnings results and hosts conference call | |
| Arrowhead Pharmaceuticals Earns $20 Mill... | 07/29/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA | |
| Arrowhead Pharmaceuticals Hosts Key Opin... | 07/28/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals and Marcus Mall MD host a webinar on ARO-ENaC for the treatment of cystic fibro... | |
| Arrowhead Pharmaceuticals Reports Induce... | 07/24/20 |
| Arrowhead reports inducement grants | |
| Arrowhead Pharmaceuticals to Host Key Op... | 07/09/20 |
| Arrowhead Pharma will host a KOL webinar on ARO-ENaC for treatment of cystic fibrosis | |
| Arrowhead Pharmaceuticals to Participate... | 05/28/20 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will present at Jefferies and Goldman Sachs healthcare conferences in June 2020 | |
| Buy rating | 09/17/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $29.00 to $31.00 | |
| Date | 2020-08-05 (AMC) | Est. (EPS/Rev.) | ($0.12)/ 28.91M |
| Actual (EPS/Rev.) | $-0.13/ $27.38 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Value Investing | Flying Colors | 88.00 % | Subscribe |
| Swingers Corner | Akemi Mokoto | 42.00 % | Follow |
| Optioneering-W | Sam Allen | 36.00 % | Follow |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
